Epaned (Enalapril Maleate) Patent Expiration, LOE Window & CMS Spending

Epaned (Enalapril Maleate) by Azurity: FDA Orange Book LOE 2036-03-25, 5 AB generics, $2.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN208686 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-03-25
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$2.6M
2024 Medicare Part D Spend$88K
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 26.4% 2-yr change)